Preclinical evaluations of dual PI3K/mTOR inhibitors, such as PI-103 and NVP-BEZ235, have demonstrated efficacy in blocking the growth of GBM cells in vitro and in vivo [9]. Here, PIK3CA is linked to glioblastoma.